RxDoctor Payments Data

Mike Liu, DO

Neurology · Fort Worth, TXNPI 1225489255

Payments from drug & device makers

$18,487in general payments, 2019–2025

Across 929 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • SK Life Science, Inc.$2K
  • Biogen$1K
  • UCB, Inc.$971
  • Livanova USA, Inc.$954
  • Pfizer$913
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$220%
  • Travel & lodging$3412%
  • Food & beverage$17,99197%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie142$2,174
SK Life Science, Inc.93$1,827
Biogen69$1,233
UCB, Inc.45$971
Livanova USA, Inc.7$954
Pfizer63$913
Novartis48$796
Amgen(2 entities)33$750
Eisai Inc.29$738
Lilly USA, LLC50$713
Argenx US, Inc.33$614
Sumitomo Pharma America, Inc.34$595
AstraZeneca(2 entities)14$532
Aucta Pharmaceuticals, Inc.25$489
Sanofi14$389
Amneal Pharmaceuticals LLC16$379
Teva Pharmaceuticals USA, Inc.11$300
Kyowa Kirin, Inc.7$260
Biohaven Pharmaceuticals, Inc.12$245
Sunovion Pharmaceuticals Inc.10$211
Upsher-smith Laboratories LLC11$204
Genentech USA, Inc.11$195
Jazz Pharmaceuticals Inc.7$193
Lundbeck LLC10$183
Avanir Pharmaceuticals, Inc.10$182
Abbott8$177
Otsuka America Pharmaceutical, Inc.10$175
Neurocrine Biosciences, Inc.1$168
Johnson & Johnson(2 entities)7$164
Biohaven Pharmaceutical Holding Company Ltd.14$148
Scilex Pharmaceuticals Inc.5$108
Nevro Corp.5$105
Cycle Pharmaceuticals Inc4$103
Corium, LLC7$94
Supernus Pharmaceuticals, Inc.5$92
Alnylam Pharmaceuticals Inc.5$92
GE HealthCare4$87
Banner Life Sciences, LLC3$74
Acadia Pharmaceuticals Inc4$71
Axsome Therapeutics, Inc.4$68
Neurelis, Inc.4$67
Springworks Therapeutics, Inc.2$62
Acorda Therapeutics, Inc3$55
Aquestive Therapeutics, Inc.3$54
Takeda Pharmaceuticals U.S.A., Inc.2$50
Currax Pharmaceuticals LLC3$41
Avion Pharmaceuticals2$37
Azurity Pharmaceuticals, Inc.2$36
Globus Medical2$35
MDD US Operations, LLC2$34
Averitas Pharma Inc.1$30
Zogenix Inc.2$28
OWP Pharmaceuticals, Inc.1$23
Grifols USA, LLC1$22
Boston Scientific1$20
TG Therapeutics, Inc.1$20
EMD Serono, Inc.1$20
Octapharma USA, Inc.1$19
Tonix Medicines, Inc.1$18
Impel Pharmaceuticals Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,487 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$333,535
Medicare patients
419
Services billed
1,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex (4 Pack)Interferon Beta-1a14$120,962
AptiomEslicarbazepine Acetate39$64,290
XcopriCenobamate29$35,424
RytaryCarbidopa/Levodopa15$31,787
NuedextaDextromethorphan Hbr/Quinidine12$20,429
Memantine Hcl455$18,759
Glatiramer Acetate11$16,430
Emgality PenGalcanezumab-Gnlm13$8,897
RivastigmineRivastigmine Tartrate111$8,495
Levetiracetam173$8,106
Carbidopa-LevodopaCarbidopa/Levodopa273$7,847
Rivastigmine25$7,262
Gabapentin192$5,626
Donepezil Hcl312$3,275
Sumatriptan Succinate28$3,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$1,233$120,96214 claims
Sunovion Pharmaceuticals Inc.Aptiom$211$64,29039 claims
SK Life Science, Inc.Xcopri$1,827$35,42429 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$379$33,42626 claims
Avanir Pharmaceuticals, Inc.Nuedexta$182$20,42912 claims
Upsher-smith Laboratories LLCTopiramate$204$1,26978 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →